Breast Cancer Coverage from Every Angle
Advertisement
Advertisement

Hope S. Rugo, MD, on Using Margetuximab in the Community Setting for HER2-Positive Metastatic Breast Cancer

Posted: Monday, June 24, 2019

Hope S. Rugo, MD, of the University of California, San Francisco, discusses the challenges for community practices of using regimens that include margetuximab for breast cancer with CD16A genotypes containing the 158F allele.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.